Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 5,478,113	$ 16,612,315
Research and development tax incentive receivable	433,852	186,507
Prepaid assets and other current assets	1,678,353	2,226,344
Total current assets	7,590,318	19,025,166
Operating lease right-of use asset, net	119,529	196,044
Property and equipment, net	1,999,781	3,078,342
Note receivable - Augmenta	2,310,000	1,812,975
Other assets	7,688	7,688
Total assets	12,027,316	24,120,215
Current liabilities:
Accounts payable	958,442	919,607
Accrued liabilities	1,285,586	4,430
Deferred research grant revenue	101,000	126,000
Current portion of operating lease liability	83,512	80,625
Total current liabilities	2,428,540	1,130,662
Operating lease liability, net of current portion	31,742	110,094
Total liabilities	2,460,282	1,240,756
Commitments and contingencies (see Note 5)
Stockholders’ equity:
Common stock; $0.001 par value, 180,000,000 shares and 45,000,000 authorized as of December 31, 2023 and 2022, respectively; 2,370,000 and 1,447,722 shares issued and outstanding as of December 31, 2023 and 2022, respectively	2,370	1,448
Additional paid-in capital	128,044,509	120,105,728
Accumulated other comprehensive loss	(148,192)	(139,295)
Accumulated deficit	(118,331,653)	(97,088,422)
Total stockholders’ equity	9,567,034	22,879,459
Total liabilities and stockholders’ equity	$ 12,027,316	$ 24,120,215